` CMPS (Compass Pathways PLC) vs S&P 500 Comparison - Alpha Spread

CMPS
vs
S&P 500

Over the past 12 months, CMPS has underperformed S&P 500, delivering a return of -42% compared to the S&P 500's +13% growth.

Stocks Performance
CMPS vs S&P 500

Loading
CMPS
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
CMPS vs S&P 500

Loading
CMPS
S&P 500
Difference
www.alphaspread.com

Performance By Year
CMPS vs S&P 500

Loading
CMPS
S&P 500
Add Stock

Competitors Performance
Compass Pathways PLC vs Peers

S&P 500
CMPS
ABBV
AMGN
GILD
VRTX
Add Stock

Compass Pathways PLC
Glance View

Market Cap
402.3m USD
Industry
Biotechnology

Compass Pathways Plc functions as an investment holding company. The company is headquartered in Altrincham, Cheshire and currently employs 116 full-time employees. The company went IPO on 2020-09-18. The firm is focused on treatment-resistant depression (TRD). The company is developing COMP360, a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. Its COMP360 psilocybin therapy comprises administration of its COMP360 with psychological support from specially trained therapists with specific professional and educational qualifications. The psilocybin administration session lasts approximately six to eight hours, with patients supported by therapists in a non-directive manner. Psilocybin administration sessions are preceded by preparation sessions, in which patients are given a thorough orientation, and followed by integration sessions to help patients process the range of emotional and physical experiences facilitated by COMP360 administration.

CMPS Intrinsic Value
Not Available
Back to Top